Millipore Corporation has entered into an agreement to acquire NovAseptic AB. The all cash transaction will result in Millipore acquiring all of the shares of NovAseptic AB for approximately SEK 720 million ($91 million at current exchange rates).

NovAseptic, based in Gothenburg, Sweden, provides a range of innovative solutions for aseptic processing applications in biotech and pharmaceutical manufacturing operations. NovAseptic's products include a unique disposable sampling system (NovaSeptum) and a range of high-performance mixers, valves, and connectors.

Martin Madaus, Millipore's Chairman, CEO and president, noted: "NovAseptic's products and customer relationships are a strong strategic fit with Millipore's Bioprocess Division. As part of our overall growth strategy, the acquisition of NovAseptic accelerates our plan to expand the breadth of our solutions to biotech and pharmaceutical customers, particularly in the areas of high-performance components and process monitoring tools."

The patented NovaSeptum disposable sampling system is used by biotech and pharmaceutical companies to take fluid samples from their drug manufacturing processes. The fully-closed system eliminates the risk of false positives due to biological contaminants, and greatly improves operator productivity and safety. NovaSeptum has been adopted by a number of pharmaceutical and biotechnology companies, and several new evaluations are in progress.

NovAseptic's other aseptic processing components include high-performance mixers and valves, optimally designed for performance and reliability in stringent drug production environments. These components enjoy an exceptional quality reputation with customers.